Table 4.
Adverse Event | Grade 1–2 n/N (%) |
Grade 3 n/N (%) |
N.a. n/N (%) |
---|---|---|---|
Anemia | 71/105 (68) | 1/105 (1) | 6/105 (6) |
Leucopenia | 44/105 (42) | 1/105 (1) | 6/105 (6) |
Neutropenia | 6/105 (6) | - | 6/105 (6) |
Neutropenic fever | - | 1/105 (1) | 6/105 (6) |
Thrombocytopenia | 38/105 (36) | - | 6/105 (6) |
Elevated creatinine | 15/105 (14) | - | 6/105 (6) |
Elevated bilirubine | 12/105 (11) | - | 6/105 (6) |
Elevated transaminases (AST/ALT) | 41/105 (39) | 2/105 (2) | 6/105 (6) |
Elevated alkaline phosphatase | 19/105 (18) | - | 6/105 (6) |
Aconuresis | 4/105 (4) | - | 7/105 (7) |
Allergic reaction | 11/105 (10) | 2/105 (2) | 7/105 (7) |
Alopecia | 5/105 (5) | - | 7/105 (7) |
Anal incontinence | 29/105 (28) | 1/105 (1) | 7/105 (7) |
Diarrhea | 74/105 (70) | 10/105 (10) | 7/105 (7) |
Dyspnea | 9/105 (9) | - | 7/105 (7) |
Emesis | 15/105 (14) | - | 7/105 (7) |
Erectile dysfunction | 9/82 (11) | 1/82 (1) | 5/82 (6) |
Fatigue | 67/105 (64) | - | 7/105 (7) |
Fever | 15/105 (14) | - | 7/105 (7) |
Hand-foot-syndrome | 7/105 (7) | - | 7/105 (7) |
Heart disorder | 5/105 (5) | - | 7/105 (7) |
Hemorrhage | 50/105 (48) | 1/105 (1) | 7/105 (7) |
Mucositis | 18/105 (17) | 1/105 (1) | 7/105 (7) |
Nausea | 39/105 (37) | 2/105 (2) | 7/105 (7) |
Non-infectious cystitis | 53/105 (50) | 2/105 (2) | 7/105 (7) |
Obstipation | 39/105 (37) | - | 7/105 (7) |
Pain | 56/105 (53) | 4/105 (4) | 7/105 (7) |
Peripheral motoric neuropathy | 8/105 (8) | - | 7/105 (7) |
Peripheral sensoric neuropathy | 64/105 (61) | - | 7/105 (7) |
Proctitis | 62/105 (59) | 3/105 (3) | 7/105 (7) |
Radiodermatitis | 71/105 (68) | 7/105 (7) | 7/105 (7) |
Urge to urinate | 40/105 (38) | - | 7/105 (7) |
Vaginal stenosis | 3/23 (13) | - | - |
Weight loss | 23/105 (22) | - | 7/105 (7) |
Other non-hematological AEs | 20/105 (19) | 7/105 (7) | 6/105 (6) |
N.a.: not available. AEs: adverse events. AST: glutamyl oxaloacetic transaminase/aspartate aminotransferase; ALT: glutamyl pyruvic transaminase/alanine aminotransferase.